Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 5:06 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 602 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Liver Fibroses Clear all
Completed Phase 2 Interventional Results available

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

NCT02802228
View directory record Official record
Conditions
Portal Hypertension, Liver Cirrhosis
Interventions
Ifetroban, Placebo
Drug
Lead sponsor
Cumberland Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
6
States / cities
Tampa, Florida • Indianapolis, Indiana • Columbus, Ohio + 3 more
Source: ClinicalTrials.gov public record
Updated Jan 19, 2022 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study in Healthy Adults Evaluating PF-07202954

NCT04857437
View directory record Official record
Conditions
Non-Alcoholic Fatty Liver Disease, Liver Fibrosis
Interventions
PF-07202954 Repeat Dose, PF-07202954 Single Dose, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Sep 20, 2024 · Synced Oct 24, 2026, 5:06 AM EDT
Enrolling by invitation Not applicable Interventional

Project OASIS: Optimizing Approaches to Select Implementation Strategies

NCT06061328
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
OASIS DA training, Current DA Tool training
Behavioral
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years and older
Enrollment
8,020 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 4, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Terminated Phase 3 Interventional

Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver

NCT00359437
View directory record Official record
Conditions
Ascites, Liver Cirrhosis
Interventions
Satavaptan, placebo
Drug
Lead sponsor
Sanofi
Industry
Eligibility
18 Years and older
Enrollment
501 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Malvern, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 24, 2016 · Synced Oct 24, 2026, 5:06 AM EDT
Recruiting Phase 2 Interventional

Liver Cirrhosis Network Rosuvastatin Efficacy and Safety for Cirrhosis in the United States

NCT05832229
View directory record Official record
Conditions
Cirrhosis, Cirrhosis, Liver, Cirrhosis Early, Cirrhosis Due to Hepatitis B, Cirrhosis Advanced, Cirrhosis Infectious, Cirrhosis Alcoholic, Cirrhosis Due to Hepatitis C
Interventions
Rosuvastatin
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 75 Years
Enrollment
260 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2029
U.S. locations
13
States / cities
La Jolla, California • Los Angeles, California • San Francisco, California + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

Phase 2 Study on Effects of Obeticholic Acid (OCA) on Lipoprotein Metabolism in Participants With Primary Biliary Cirrhosis

NCT01865812
View directory record Official record
Conditions
Primary Biliary Cirrhosis
Interventions
Obeticholic Acid
Drug
Lead sponsor
Intercept Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
7
States / cities
La Jolla, California • Sacramento, California • Miami, Florida + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2022 · Synced Oct 24, 2026, 5:06 AM EDT
Withdrawn No phase listed Observational

The Regression of Liver Fibrosis and Risk for Hepatocellular Carcinoma (ROLFH) Study

NCT01831037
View directory record Official record
Conditions
Chronic Hepatitis C, Chronic Hepatitis B
Interventions
Regression of fibrosis, Specific risk factors related to hepatocellular carcinoma
Other
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
2
States / cities
Little Rock, Arkansas • Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study in Participants With Non-cirrhotic NASH With Fibrosis

NCT05638737
View directory record Official record
Conditions
Non-Cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
AZD4831, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
17
States / cities
Chandler, Arizona • Tucson, Arizona • Chula Vista, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Emricasan, a Caspase Inhibitor, for Evaluation in Subjects With Non-Alcoholic Steatohepatitis (NASH) Fibrosis

NCT02686762
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis, Fibrosis, Liver Diseases
Interventions
Emricasan (5 mg), Emricasan (50 mg), Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
318 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
83
States / cities
Birmingham, Alabama • Tucson, Arizona • Little Rock, Arkansas + 63 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Erlotinib Hydrochloride in Preventing Liver Cancer in Patients With Cirrhosis of the Liver

NCT02273362
View directory record Official record
Conditions
Cirrhosis, Hepatocellular Carcinoma
Interventions
Erlotinib, Erlotinib Hydrochloride, Laboratory Biomarker Analysis, Quality-of-Life Assessment
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
6
States / cities
Jacksonville, Florida • Boston, Massachusetts • Rochester, Minnesota + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 26, 2024 · Synced Oct 24, 2026, 5:06 AM EDT
Terminated Phase 1 Interventional Results available

A Study to Evaluate How Ontamalimab Works and Assess Its Safety and Tolerability in People With Nonalcoholic Steatohepatitis With Fibrosis Stages 1 to 4

NCT07052682
View directory record Official record
Conditions
Steatohepatitis
Interventions
Ontamalimab
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
15
States / cities
Chandler, Arizona • Tucson, Arizona • Coronado, California + 11 more
Source: ClinicalTrials.gov public record
Updated Aug 19, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Recruiting Phase 1 Interventional

Single and Multiple Dose Escalation of PHIN-214 in Child-Pugh A and B Liver Cirrhotics

NCT05490888
View directory record Official record
Conditions
Cirrhosis, Liver, Liver Fibrosis, Ascites Hepatic
Interventions
PHIN-214 Subcutaneous injection
Drug
Lead sponsor
PharmaIN
Industry
Eligibility
18 Years to 75 Years
Enrollment
74 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
9
States / cities
Chandler, Arizona • Coronado, California • Marrero, Louisiana + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Not yet recruiting Not applicable Interventional

Screening Cardiometabolic Opportunities Using Transformative Echocardiography Artificial Intelligence (SCOUT Echo-AI)

NCT07216859
View directory record Official record
Conditions
MASLD - Metabolic Dysfunction-Associated Steatotic Liver Disease, Cirrhosis
Interventions
AI-Enabled Identification (EchoNet-Liver)
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2028
U.S. locations
6
States / cities
Los Angeles, California • Palo Alto, California • Pleasanton, California + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Recruiting No phase listed Observational

Natural History of Noncirrhotic Portal Hypertension

NCT02417740
View directory record Official record
Conditions
Cystic Fibrosis, Immunologic Deficiency Syndrome, Turner Syndrome, Congenital Hepatic Fibrosis, Idiopathic Non-Cirrhotic Portal Hypertension
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
12 Years to 100 Years
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2029
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 15, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety, Tolerability, PK, and PD Effects of AZD2389 in Participants With Liver Fibrosis and Compensated Cirrhosis.

NCT06750276
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Cirrhosis
Interventions
AZD2389
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
7
States / cities
Chandler, Arizona • Rialto, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

A Study to Evaluate AZD2693 in Participants Who Are Carriers of the PNPLA3 148M Risk Allele With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05809934
View directory record Official record
Conditions
Nonalcoholic Steatohepatitis
Interventions
AZD2693, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
220 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
37
States / cities
Chandler, Arizona • Peoria, Arizona • Surprise, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Oct 28, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Treatment of Nonalcoholic Steatohepatitis With Pioglitazone

NCT00013598
View directory record Official record
Conditions
Fatty Liver, Nonalcoholic Steatohepatitis
Interventions
Pioglitazone
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
Not listed
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2004
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 24, 2026, 5:06 AM EDT
Not listed No phase listed Observational Accepts healthy volunteers

PatientSpot Formerly Known as ArthritisPower

NCT03840928
View directory record Official record
Conditions
Rheumatoid Arthritis, Ankylosing Spondylitis, Fibromyalgia, Gout, Crohn Disease, Juvenile Idiopathic Arthritis, Lupus Erythematosus, Myositis, Osteoarthritis, Osteoporosis, Psoriasis, Psoriatic Arthritis, Scleroderma, Dermatomyositis, Inflammatory Bowel Diseases, Polymyositis, Axial Spondyloarthritis, Diffuse Idiopathic Skeletal Hyperostosis, Polymyalgia Rheumatica, Giant Cell Arteritis, Temporal Arteritis, Wegener, Relapsing Polychondritis, Undifferentiated Connective Tissue Disease, Spinal Cord Injuries, Alzheimer Disease, Amyotrophic Lateral Sclerosis, Ataxia, Bell Palsy, Brain Tumor, Cerebral Aneurysm, Epilepsy, Guillain-Barre Syndrome, Headache, Head Injury, Hydrocephalus, Lumbar Disc Disease, Meningitis, Multiple Sclerosis, Muscular Dystrophy, Neurocutaneous Syndromes, Parkinson Disease, Stroke, Cluster Headache, Tension-Type Headache, Chronic Obstructive Pulmonary Disease, Asthma, Lung Cancer, Cystic Fibrosis, Sleep Apnea, Eczema, Alopecia, Chronic Inflammation, Unstable Angina, Heart Attack, Heart Failure, Arrythmia, Valve Heart Disease, High Blood Pressure, Congenital Heart Disease, Peripheral Arterial Disease, Diabetes, Chronic Liver Disease, Obesity
Interventions
Not listed
Lead sponsor
Global Healthy Living Foundation
Other
Eligibility
19 Years and older
Enrollment
40,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Upper Nyack, New York
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 3 Interventional Results available

Long Term Interferon for Patients Who Did Not Clear Hepatitis C Virus With Standard Treatment

NCT00006164
View directory record Official record
Conditions
Chronic Hepatitis c, Cirrhosis, Liver, Fibrosis, Liver, Hepatic Cirrhosis
Interventions
Peginterferon alfa-2a + Ribavirin, Peginterferon alfa-2a
Drug
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years and older
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2009
U.S. locations
11
States / cities
Long Beach, California • Los Angeles, California • Denver, Colorado + 8 more
Source: ClinicalTrials.gov public record
Updated May 12, 2020 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

B-mode Ultrasound Imaging in Detecting Early Liver Cancer

NCT02774161
View directory record Official record
Conditions
Cirrhosis, Early Hepatocellular Carcinoma, Fibrosis, Stage I Hepatocellular Carcinoma, Stage II Hepatocellular Carcinoma
Interventions
Ultrasound Tomography
Other
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
45 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2021 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Trial of IDN-6556 in Post Orthotopic Liver Transplant for Chronic HCV

NCT02138253
View directory record Official record
Conditions
Liver Fibrosis, Hepatic Fibrosis, Liver Cirrhosis, Hepatic Cirrhosis
Interventions
IDN-6556, Placebo
Drug
Lead sponsor
Conatus Pharmaceuticals Inc.
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
35
States / cities
Coronado, California • La Jolla, California • Loma Linda, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 1 Interventional

Oral Fecal Transplant in Cirrhosis

NCT03152188
View directory record Official record
Conditions
Hepatic Encephalopathy, Cirrhosis, Liver
Interventions
FMT, Placebo
Drug · Other
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
21 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated May 19, 2021 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Cotadutide Given by Subcutaneous Injection in Adult Participants With Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis

NCT05364931
View directory record Official record
Conditions
Non-cirrhotic Non-alcoholic Steatohepatitis With Fibrosis
Interventions
Cotadutide, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 75 Years
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
29
States / cities
Tucson, Arizona • Canoga Park, California • Gilroy, California + 23 more
Source: ClinicalTrials.gov public record
Updated Sep 3, 2025 · Synced Oct 24, 2026, 5:06 AM EDT
Completed Phase 2 Interventional

Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

NCT05327127
View directory record Official record
Conditions
NASH
Interventions
K-877-ER, CSG452, Placebo
Drug
Lead sponsor
Kowa Research Institute, Inc.
Industry
Eligibility
18 Years and older
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
37
States / cities
Tucson, Arizona • Little Rock, Arkansas • Lincoln, California + 30 more
Source: ClinicalTrials.gov public record
Updated Jun 26, 2026 · Synced Oct 24, 2026, 5:06 AM EDT